

**Report of Voting Results for Annual Meeting of Shareholders on September 21, 2023
(National Instrument 51-102 – Continuous Disclosure Obligations, section 11.3)**

Medexus Pharmaceuticals Inc. (**Company**) held its virtual annual meeting of shareholders on September 21, 2023. Shareholders holding 36.90% of the issued and outstanding common shares of the Company as of the record date of August 8, 2023 were represented in person or by proxy at the meeting.

Voting on all matters at the meeting was conducted by ballot. All matters put to a ballot were passed with the requisite shareholder approval. The detailed results are set out below.

Election of directors

(a) Each of the seven nominees in the Company's management information circular dated August 9, 2023 (**Proxy Circular**) was elected to serve until the next annual meeting of shareholders of the Company or until their successor is duly elected or appointed.

(b) The percentages of votes cast for and against the election of each director are set out below.

Name	For	Against
Ken d'Entremont	99.40% (6,610,209)	0.60% (39,627)
Harmony Garges	99.43% (6,612,024)	0.57% (37,812)
Benoit Gravel	99.40% (6,610,199)	0.60% (39,637)
Michael Mueller	99.43% (6,612,024)	0.57% (37,812)
Stephen Nelson	99.39% (6,609,409)	0.61% (40,427)
Nancy Phelan	99.42% (6,611,224)	0.58% (38,612)
Menassie Taddese	99.39% (6,609,409)	0.61% (40,427)

Appointment of auditors

(a) The appointment of PricewaterhouseCoopers LLP as auditors of the Company for the ensuing year and the authorization of the directors to fix their remuneration as such was approved with the requisite shareholder approval.

(b) The percentages of votes cast for and withheld from the vote on the appointment of the Company's auditors are set out below.

Matter	For	Withheld
---------------	------------	-----------------

Appointment of PricewaterhouseCoopers LLP, Chartered Accountants as auditors of the Company for the ensuing year and authorizing the directors to fix their remuneration	99.55% (7,498,887)	0.45% (33,641)
--	--------------------	----------------

Amendment of equity incentive compensation plan

(a) The resolutions to amend the Company's equity compensation plan, as more fully described in the Proxy Circular, were passed with the requisite shareholder approval.

(b) The percentages of votes cast for and against the resolutions are set out below.

Matter	For	Against
Consideration and approval of resolutions to amend the Company's equity incentive compensation plan	98.76% (6,567,139)	1.24% (82,697)

Executed by the undersigned on behalf of the Company on September 21, 2023.

Medexus Pharmaceutical Inc.

By: /s/ Ian Craig Wildgoose Brown
Name: Ian Craig Wildgoose Brown
Title: Corporate Secretary